Difference between revisions of "Irinotecan (Camptosar)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - ": new" to ": New") |
m |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 19: | Line 19: | ||
*[[Gastric cancer]] | *[[Gastric cancer]] | ||
*[[Glioblastoma]] | *[[Glioblastoma]] | ||
| + | *[[Hepatoblastoma]] | ||
*[[Neuroblastoma]] | *[[Neuroblastoma]] | ||
*[[Non-small cell lung cancer]] | *[[Non-small cell lung cancer]] | ||
| Line 34: | Line 35: | ||
* 1996-06-14: Initial accelerated approval for the treatment of patients with metastatic [[Colorectal cancer|carcinoma of the colon or rectum]] whose disease has recurred or progressed following [[Fluorouracil (5-FU) | 5-FU-based]] therapy. ''(Based on Rothenberg et al. 1996, Pitot et al. 1997, Rougier et al. 1997, and Rothenberg et al. 1999)'' | * 1996-06-14: Initial accelerated approval for the treatment of patients with metastatic [[Colorectal cancer|carcinoma of the colon or rectum]] whose disease has recurred or progressed following [[Fluorouracil (5-FU) | 5-FU-based]] therapy. ''(Based on Rothenberg et al. 1996, Pitot et al. 1997, Rougier et al. 1997, and Rothenberg et al. 1999)'' | ||
**1998-10-22: Converted to regular approval for the treatment of patients with metastatic [[Colorectal cancer|carcinoma of the colon or rectum]] whose disease has recurred or progressed following [[Fluorouracil (5-FU) | 5-FU-based]] therapy. ''(Based on V301 & V302)'' | **1998-10-22: Converted to regular approval for the treatment of patients with metastatic [[Colorectal cancer|carcinoma of the colon or rectum]] whose disease has recurred or progressed following [[Fluorouracil (5-FU) | 5-FU-based]] therapy. ''(Based on V301 & V302)'' | ||
| − | * 2000-04-20: Indicated as a component of first-line therapy in combination with [[Fluorouracil (5-FU) | 5-fluorouracil]] and [[Folinic acid | + | * 2000-04-20: Indicated as a component of first-line therapy in combination with [[Fluorouracil (5-FU) | 5-fluorouracil]] and [[Leucovorin (Folinic acid) | leucovorin]] for patients with metastatic [[Colorectal cancer|carcinoma of the colon or rectum]]. ''(Based on Douillard et al. 2000 & Saltz et al. 2000)'' |
| + | ==History of changes in EMA indication== | ||
| + | *1995-05-05: EURD | ||
==History of changes in PMDA indication== | ==History of changes in PMDA indication== | ||
*2013-03-25: New additional indication and a new dosage for the treatment of pediatric [[:Category:Malignant solid neoplasm|malignant solid tumor]]. | *2013-03-25: New additional indication and a new dosage for the treatment of pediatric [[:Category:Malignant solid neoplasm|malignant solid tumor]]. | ||
| Line 51: | Line 54: | ||
[[Category:Irritant]] | [[Category:Irritant]] | ||
| − | [[Category:Topoisomerase inhibitors]] | + | [[Category:Topoisomerase I inhibitors]] |
[[Category:Carcinoma of unknown primary medications]] | [[Category:Carcinoma of unknown primary medications]] | ||
| Line 64: | Line 67: | ||
[[Category:Gastric cancer medications]] | [[Category:Gastric cancer medications]] | ||
[[Category:Glioblastoma medications]] | [[Category:Glioblastoma medications]] | ||
| + | [[Category:Hepatoblastoma medications]] | ||
[[Category:Neuroblastoma medications]] | [[Category:Neuroblastoma medications]] | ||
| + | [[Category:Neuroendocrine carcinoma medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:Pancreatic cancer medications]] | [[Category:Pancreatic cancer medications]] | ||
| Line 73: | Line 78: | ||
[[Category:FDA approved in 1996]] | [[Category:FDA approved in 1996]] | ||
| + | [[Category:EMA approved in 1995]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 00:41, 7 November 2023
General information
Class/mechanism: Topoisomerase I inhibitor; derivative of camptothecin, which interferes with topoisomerase I's normal action of relieving torsional strain in DNA by creating reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I & DNA complex and interfere with ligation of these single-strand breaks. Failure to repair these breaks eventually leads to double-strand DNA damage, which disrupts cell proliferation and leads to cell death.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Carcinoma of unknown primary
- Anaplastic glioma
- Cervical cancer
- Colorectal cancer
- Esophageal cancer
- Ewing sarcoma
- Gallbladder cancer
- Gastric cancer
- Glioblastoma
- Hepatoblastoma
- Neuroblastoma
- Non-small cell lung cancer
- Pancreatic cancer
- Penile cancer
- Rhabdomyosarcoma
- Small cell lung cancer
Patient drug information
- Irinotecan (Camptosar) package insert[1]
- Irinotecan (Camptosar) patient drug information (Chemocare)[3]
- Irinotecan (Camptosar) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1996-06-14: Initial accelerated approval for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy. (Based on Rothenberg et al. 1996, Pitot et al. 1997, Rougier et al. 1997, and Rothenberg et al. 1999)
- 1998-10-22: Converted to regular approval for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy. (Based on V301 & V302)
- 2000-04-20: Indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum. (Based on Douillard et al. 2000 & Saltz et al. 2000)
History of changes in EMA indication
- 1995-05-05: EURD
History of changes in PMDA indication
- 2013-03-25: New additional indication and a new dosage for the treatment of pediatric malignant solid tumor.
- 2013-12-20: New additional indication and a new dosage for the treatment of unresectable pancreatic cancer.
Also known as
- Generic name: irinotecan hydrochloride trihydrote
- Code names: Camptothecin-11, CPT-11, U-101440E
- Brand names: Axinotecan, Biotecan, Biskam, Campto, Campostar, Camptosar, Elinatecan, Faultenocan, Irenax, Irinogen, Irinomedac, Irinotel, Irinotesin, Irnocam, Itoxaril, Linatecan, Satigene, Tecnotecan, Tekamen, Toptecin, Trinotecan, Winol
References
Categories:
- Drugs
- Intravenous medications
- Irritant
- Topoisomerase I inhibitors
- Carcinoma of unknown primary medications
- Anaplastic glioma medications
- Cervical cancer medications
- Colorectal cancer medications
- Esophageal adenocarcinoma medications
- Esophageal cancer medications
- Esophageal squamous cell carcinoma medications
- Ewing sarcoma medications
- Gallbladder cancer medications
- Gastric cancer medications
- Glioblastoma medications
- Hepatoblastoma medications
- Neuroblastoma medications
- Neuroendocrine carcinoma medications
- Non-small cell lung cancer medications
- Pancreatic cancer medications
- Penile cancer medications
- Rectal cancer medications
- Rhabdomyosarcoma medications
- Small cell lung cancer medications
- FDA approved in 1996
- EMA approved in 1995
- WHO Essential Cancer Medicine